

AD _____

Award Number: DAMD17-03-1-0173

TITLE: Function of Human Selenium-Binding Protein in Selenium
Induced Growth Arrest and Apoptosis in Prostate Cancer
Cells

PRINCIPAL INVESTIGATOR: Natasa Debeljak, Ph.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center
Boston, MA 02215

REPORT DATE: April 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060110 064

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY
(Leave blank)**2. REPORT DATE**
April 2005**3. REPORT TYPE AND DATES COVERED**
Annual Summary (1 Apr 04 - 31 Mar 05)**4. TITLE AND SUBTITLE**

Function of Human Selenium-Binding Protein in Selenium Induced Growth Arrest and Apoptosis in Prostate Cancer Cells

5. FUNDING NUMBERS

DAMD17-03-1-0173

6. AUTHOR(S)

Natasa Debeljak, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Beth Israel Deaconess Medical Center
Boston, MA 02215

E-Mail: ndebelja@bidmc.harvard.edu

**8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING / MONITORING
AGENCY NAME(S) AND ADDRESS(ES)**

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

The aim of the study is to elucidate the role of human selenium binding protein (hSP56) in selenium induced cell apoptosis in cancer cells. During the second year of the project we demonstrated that the human prostate (PC-3) cells overexpressing hSP56 protein show changed growth characteristic and increased sensitivity to selenium compounds. To understand the biological role(s) of hSP56, a yeast two-hybrid screening has been performed to identify the proteins interacting with hSP56 from human prostate cDNA library. The screening identified two potential proteins as interacting partners of hSP56, Ubc12 and VDU1. Both proteins are involved in ubiquitination-mediated protein degradation pathway. We hypothesize that hSP56 regulates the protein degradation pathway by altering the properties of Ubc12 and/or VDU1.

14. SUBJECT TERMS

Selenium, gene expression, gain-of-function, loss-of-function, cDNA, microarray

15. NUMBER OF PAGES

6

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Annual Summary.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	
Conclusions.....	
References.....	
Appendices.....	

Annual Summary

The aim of the study is to identify the role of human selenium binding protein (hSP56) in selenium induced cell death in human prostate cancer. Previously, our laboratory identified hSP56 as one of the proteins expressed in the slow-growing human prostate cancer cell line, LNCaP, but not in the fast-growing human prostate cancer cell line, PC-3. During the first year of the project two types of cancer cell lines with modified hSP56 expression have been prepared. Anti-sense RNA mediated method was used to suppress the of endogenous hSP56 gene expression in LNCaP cells. The mammalian expression plasmid encoding hSP56 gene has been used to obtain PC-3 cells with inducible expression of exogenous hSP56 protein. Additionally, metabolic labeling followed by immunoprecipitation demonstrated that hSP56 contains covalent selenium, indicating that the hSP56 protein interacts with selenium in a different way from other types of selenium-containing proteins (e.g. glutathione peroxidase and selenoprotein P) that have selenium incorporated into the polypeptide as selenocysteine.

In the second year of the training the effect of up-regulation of hSP56 in the prostate cancer cell line PC-3 with the inducible expression of exogenous hSP56 protein were studied. When induced by tetracycline, this cell line is capable of expressing many folds higher level of hSP56 protein. The overexpression of hSP56 in PC-3 cells has changed cell growth characteristic and made the cell line more sensitive to selenium compounds like known for the LNCaP cells (manuscript in preparation). This indicates that hSP56 may be a key molecule responsible for the selenium mediated cell growth blockade observed in the slow-growing, androgen-responsive human prostate cancer cell line, LNCaP cells.

However, little is known about hSP56's mechanism. Despite the implication of hSP56 in selenium-mediated cell cycle control, its functions and signaling pathways have not been characterized. Pattern and motif searches with the deduced amino acid sequences of hSP56 revealed no important functional sites or signatures. We hypothesized that hSP56 functions through protein-protein interactions.

Therefore, the experiments to identify proteins interacting with hSP56 using yeast two-hybrid screening were carried out. We used the full-length hSP56 as bait and screened over 4×10^6 colonies obtained from the human prostate cDNA library. The C-terminal 172 amino acids of pVHL-interacting deubiquitinating enzyme (VDU1) and the full-length NEDD8 conjugating enzyme (Ubc12) were identified as potential interacting protein partners of hSP56. For both Ubc12 and VDU1 fragment, the activation of the reporter genes was observed only with the hSP56 containing bait plasmid and not with the control bait plasmid. This experiment confirmed the specificity of the interactions in the yeast two-hybrid system.

Ubc12 and VDU1 proteins are involved in ubiquitin-mediated protein degradation pathways, suggesting that hSP56 also takes important part in regulating the protein degeneration. Based on these findings, several addition experiments are being performed to furtherer characterize the interactions between hSP56 and Ubc12 or VDU1 and to explore the biological significance of the interactions. All proteins were expressed and purified from bacteria and we are confirming the interactions by *in vitro* binding assay. *In vivo* interactions are also being examined by co-immunoprecipitation experiment. The effect of selenium compounds on the interactions and the biological significance of the interactions will also be explored.

Key accomplishment

- Stably transfected PC-3 cells overexpressing hSP56 protein showed a changed growth characteristic and increased sensitivity to selenium compounds.
- This indicates that hSP56 may be a key molecule responsible for the selenium mediated cell growth blockade observed in LNCaP cells.
- The yeast two-hybrid system has identified several potential hSP56 interacting partners, including pVHL-interacting deubiquitinating enzyme (VDU1) and NEDD8 conjugating enzyme (Ubc12).
- Both VDU1 and Ubc12 are involved in ubiquitination-mediated protein degradation indicating the role of hSP56 in this process.